These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 27228176)

  • 1. WITHDRAWN: Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
    Epstein T; Patsopoulos NA; Weiser M
    Cochrane Database Syst Rev; 2016 May; (5):CD005041. PubMed ID: 27228176
    [No Abstract]   [Full Text] [Related]  

  • 2. Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
    Epstein T; Patsopoulos NA; Weiser M
    Cochrane Database Syst Rev; 2014 Sep; (9):CD005041. PubMed ID: 25230710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy and safety of stimulants and non-stimulants in adults with attention deficit hyperactivity disorder (ADHD)].
    Golubchik P; Sever J; Weizman A
    Harefuah; 2011 Oct; 150(10):788-90, 814. PubMed ID: 22111124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transdermal methylphenidate (Daytrana) for ADHD.
    Med Lett Drugs Ther; 2006 Jun; 48(1237):49-51. PubMed ID: 16785850
    [No Abstract]   [Full Text] [Related]  

  • 5. Responses to methylphenidate in Attention-Deficit/Hyperactivity Disorder and normal children: update 2002.
    Rapoport JL; Inoff-Germain G
    J Atten Disord; 2002; 6 Suppl 1():S57-60. PubMed ID: 12685519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comments on efficacy and tolerability of OROS methylphenidate in Korean children with attention-deficit/hyperactivity disorder.
    Pae CU
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1149-50; author reply 1151-2. PubMed ID: 17493730
    [No Abstract]   [Full Text] [Related]  

  • 7. The Jury Is Still Out on the Benefits and Harms of Methylphenidate for Children and Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Storebø OJ; Faltinsen E; Zwi M; Simonsen E; Gluud C
    Clin Pharmacol Ther; 2018 Oct; 104(4):606-609. PubMed ID: 30006934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving decision making in the treatment of ADHD.
    Vitiello B
    Am J Psychiatry; 2008 Jun; 165(6):666-7. PubMed ID: 18519529
    [No Abstract]   [Full Text] [Related]  

  • 9. Focalin XR for ADHD.
    Med Lett Drugs Ther; 2009 Mar; 51(1308):22-4. PubMed ID: 19305368
    [No Abstract]   [Full Text] [Related]  

  • 10. Is the evidence base of methylphenidate for children and adolescents with attention-deficit/hyperactivity disorder flawed?
    Hoekstra PJ; Buitelaar JK
    Eur Child Adolesc Psychiatry; 2016 Apr; 25(4):339-40. PubMed ID: 27021055
    [No Abstract]   [Full Text] [Related]  

  • 11. Increase in Menstrual Cycle Length Induced by Extended-Release Methylphenidate in an Adolescent with Attention-Deficit/Hyperactivity Disorder.
    Mutlu C; Bahalı K; Gunes H; Adaletli H
    J Child Adolesc Psychopharmacol; 2016 Nov; 26(9):860-861. PubMed ID: 26397126
    [No Abstract]   [Full Text] [Related]  

  • 12. ADHD, methylphenidate and driving: does some legislation endanger public health?
    Verster JC; Cox DJ
    J Psychopharmacol; 2008 May; 22(3):227-9. PubMed ID: 18541623
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacology of adult ADHD with stimulants.
    Spencer TJ
    CNS Spectr; 2007 Apr; 12(4 Suppl 6):8-11. PubMed ID: 17715564
    [No Abstract]   [Full Text] [Related]  

  • 14. The preschool ADHD Treatment Study (PATS) as the culmination of twenty years of clinical trials in pediatric psychopharmacology.
    March JS
    J Am Acad Child Adolesc Psychiatry; 2011 May; 50(5):427-30. PubMed ID: 21515189
    [No Abstract]   [Full Text] [Related]  

  • 15. Predictors of placebo response in adults with attention-deficit/hyperactivity disorder: data from 2 randomized trials of osmotic-release oral system methylphenidate.
    Buitelaar JK; Sobanski E; Stieglitz RD; Dejonckheere J; Waechter S; Schäuble B
    J Clin Psychiatry; 2012 Aug; 73(8):1097-102. PubMed ID: 22780962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methylphenidate for attention-deficit/hyperactivity disorder: The longest debate.
    Levy F
    Aust N Z J Psychiatry; 2016 Jul; 50(7):616-7. PubMed ID: 27066820
    [No Abstract]   [Full Text] [Related]  

  • 17. Attention deficit hyperactivity disorder in children.
    Ramchandani P; Joughin C; Zwi M
    Clin Evid; 2002 Jun; (7):262-71. PubMed ID: 12230649
    [No Abstract]   [Full Text] [Related]  

  • 18. Attention deficit and hyperactivity disorder, methylphenidate, and epilepsy.
    Tan M; Appleton R
    Arch Dis Child; 2005 Jan; 90(1):57-9. PubMed ID: 15613514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Venlafaxine versus methylphenidate in pediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial.
    Zarinara AR; Mohammadi MR; Hazrati N; Tabrizi M; Rezazadeh SA; Rezaie F; Akhondzadeh S
    Hum Psychopharmacol; 2010 Nov; 25(7-8):530-5. PubMed ID: 20860068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroendocrine responses to methylphenidate and d-amphetamine: applications to attention-deficit disorder.
    Lurie S; O'Quinn A
    J Neuropsychiatry Clin Neurosci; 1991; 3(1):41-50. PubMed ID: 7580171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.